Top in endocrinology: SGLT2s vs. GLP-1s in older adults; weight cycling in type 1 diabetes
Sodium-glucose cotransporter 2, or SGLT2, inhibitors may be more cardioprotective for older adults, whereas glucagon-like peptide-1 receptor agonists may confer greater HbA1c reductions in that population, according to a systematic review and meta-analysis.
The researchers obtained data from 601 randomized controlled trials. They found that treatment with SGLT2 inhibitors, GLP-1 receptor agonists or dipeptidyl peptidase 4 (DPP-4) inhibitors lowered HbA1c but only SGLT2 inhibitors and GLP-1 receptor agonists lowered the risk for major adverse cardiovascular events compared with placebo.
“We need more evidence to guide our treatment of people in much older age and who are living with frailty,” Peter Hanlon, PhD, clinical senior research fellow in the School of Health and Wellbeing at University of Glasgow in the U.K., told Healio.
It was the top story in endocrinology last week.
In another top story, adults with type 1 diabetes who repeatedly lose and regain body weight were more likely to develop diabetic kidney disease, researchers found in what they believe is the first study to show this association.
Read these and more top stories in endocrinology below:
SGLT2 inhibitors may offer more cardioprotective benefits than GLP-1s for older adults
SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes compared with younger adults, according to findings from a systematic review and meta-analysis published in JAMA. Read more.
Weight cycling may worsen kidney function for adults with type 1 diabetes
Adults with type 1 diabetes who partake in weight cycling and repeatedly lose and regain body weight are more likely to develop diabetic kidney disease, researchers reported in The Journal of Clinical Endocrinology & Metabolism. Read more.
DHEAS may serve as biomarker for diagnosing adrenal insufficiency
The use of dehydroepiandrosterone sulfate to determine an adrenal insufficiency diagnosis has similar accuracy to using baseline cortisol level, according to findings published in The Journal of Clinical Endocrinology & Metabolism. Read more.
CGM may lead to lower health care costs for pregnant women with type 1 diabetes
The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for women with type 1 diabetes, according to a brief report published in Diabetes Technology & Therapeutics. Read more.
Wegovy may reduce need for antihypertensive, lipid-lowering therapies
Adults receiving semaglutide for the treatment of obesity were more likely to have antihypertensive or lipid-lowering therapy tapered or discontinued than those receiving placebo, according to data from the STEP trials. Read more.